News | July 24, 2021
Lonza reports strong momentum in H1 2021
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
The facility is expected to be completed in 2024
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Subscribe To Our Newsletter & Stay Updated
